Forian Inc. (Nasdaq: FORA) reported financial results for the fourth quarter and full year ended December 31, 2025, showing substantial revenue growth while navigating strategic investments and potential corporate changes. The company, which provides data science-driven information and analytics solutions to life sciences, healthcare, and financial services industries, achieved a 50% increase in annual revenue to $30.3 million from $20.2 million in 2024.
Chief Executive Officer Max Wygod stated that 2025 demonstrated how disciplined cost management and strategic investment can work together. The company grew its business, expanded into new markets, and made targeted investments in its data platform and product development while maintaining a cost-conscious approach that preserved balance sheet strength. For more detailed information about the company's offerings, visit https://www.forian.com.
Fourth quarter revenue reached $8.0 million, representing a 37% increase from $5.8 million in the prior year period. However, the company reported a net loss of $(1.8) million for the quarter, or $(0.06) per share, compared to net income of $0.2 million, or $0.01 per share, in the fourth quarter of 2024. Adjusted EBITDA, a non-GAAP financial measure, was $(0.2) million for the quarter compared to $0.1 million in the prior year period.
For the full year, net loss improved to $(2.9) million, or $(0.09) per share, compared to a net loss of $(3.8) million, or $(0.12) per share, in 2024. Adjusted EBITDA for the full year increased 72% to $0.8 million from $0.5 million in the prior year. The company ended the year with $31.6 million in cash, cash equivalents, and marketable securities.
Key achievements for 2025 included meeting revenue guidance targets through strong quarterly performance driven by key contract renewals that offset churn and data supply challenges. The company also achieved its targeted margin profile for Adjusted EBITDA while continuing meaningful investments across the business. Forian strengthened its data platform and partnerships by expanding contracting activity and onboarding new clinical data feeds, addressing upstream data supply challenges and broadening the company's data foundation.
The company reported growing pharmaceutical and biotech footprint as life sciences customers increasingly adopted Forian's data and analytics offerings. This expansion into traditional and emerging life sciences segments represents a significant market opportunity as healthcare organizations seek more sophisticated data management and analytics capabilities.
A notable corporate development update revealed that on August 25, 2025, a consortium led by Forian's Chief Executive Officer and Executive Chair submitted a non-binding proposal to acquire all outstanding shares of Common Stock not currently owned by the consortium. A Special Committee formed to evaluate this proposal remains in place and is in discussions with the consortium regarding the proposal. The company noted there can be no assurance that any transaction will result from these discussions.
The financial results highlight the balancing act many technology companies face between growth investment and profitability. Forian's substantial revenue growth indicates strong market demand for its data science and analytics solutions, particularly in the life sciences sector where data-driven decision making is becoming increasingly critical. However, the mixed profitability metrics suggest the company is prioritizing growth and platform development over immediate earnings, a common strategy in competitive technology markets.
The potential acquisition discussion adds another layer of complexity to Forian's strategic position. If the consortium's proposal moves forward, it could significantly impact the company's direction and ownership structure. For business leaders in the data analytics and life sciences sectors, Forian's performance demonstrates both the opportunities in healthcare data analytics and the challenges of scaling while managing profitability. The company's ability to grow revenue substantially while improving its net loss position year-over-year suggests effective operational management despite increased investment activity.
Forian's focus on expanding its data platform and partnerships addresses a critical need in the healthcare analytics market where data quality and accessibility remain significant challenges. The company's progress in onboarding new clinical data feeds and strengthening partnerships could position it well for future growth as healthcare organizations increasingly rely on comprehensive data solutions to optimize operational, clinical, and financial performance. The original financial release can be viewed at https://www.newmediawire.com.
